AEON Biopharma has amended the terms of its outstanding two-year milestone warrants to lower the exercise price, a move expected to generate approximately $6.2 million in gross proceeds. The amendment is intended to encourage the exercise of these warrants before their upcoming expiration.
Key Details
- Agreement: On November 2, 2026, AEON entered into an amendment for its milestone warrants originally issued on July 15, 2026.
- Reduced Exercise Price: The exercise price was reduced from $0.3221 to $0.20 per share of Common Stock, and from $0.3220 to $0.1999 per Pre-Funded Warrant.
- Financial Impact: As a result of the price reduction, certain holders have agreed to exercise their warrants, and the company anticipates receiving approximately $6.2 million in gross proceeds.
- Expiration Date: The warrants are set to expire on November 16, 2026. The amendment applies to all outstanding two-year warrants, with all other terms remaining unchanged.